SK Pharma

Semaglutide injection (brand names Ozempic, Wegovy) is a weekly, self-administered subcutaneous medication primarily used for managing Type 2 diabetes and promoting weight loss. It works by mimicking the GLP-1 hormone to regulate insulin, decrease appetite, and improve glycemic control. It is also approved for reducing cardiovascular risks in adults with heart disease, such as heart attacks and strokes, and to aid in long-term weight management.

Semaglutide 1.7 mg injection (often branded as Wegovy) is a once-weekly prescription medication used for long-term weight management in adults with obesity or overweight (with comorbidities) and for reducing cardiovascular risks. It works by mimicking a hormone that slows gastric emptying and reduces appetite. 
DailyMed (.gov) +4

Semaglutide 1.7 mg injection (often branded as Wegovy) is a once-weekly prescription medication used for long-term weight management in adults with obesity or overweight (with comorbidities) and for reducing cardiovascular risks. It works by mimicking a hormone that slows gastric emptying and reduces appetite.
DailyMed (.gov)
DailyMed (.gov)
+4

Semaglutide 1.7 mg injection (often branded as Wegovy) is a once-weekly prescription medication used for long-term weight management in adults with obesity or overweight (with comorbidities) and for reducing cardiovascular risks. It works by mimicking a hormone that slows gastric emptying and reduces appetite. 
DailyMed (.gov) +4

Semaglutide 0.25mg injection (Ozempic, Wegovy, Poviztra) is a once-weekly, subcutaneous, starter-dose injection used to treat type 2 diabetes or for chronic weight management. It acts as a GLP-1 receptor agonist, reducing appetite and slowing gastric emptying to aid in blood sugar control and weight loss, typically for the first 4 weeks.
1mg
1mg
+5

Semaglutide 2.4 mg injection (commonly branded as Wegovy) is a once-weekly subcutaneous injection used for chronic weight management and reducing cardiovascular risks in adults with obesity or overweight. It mimics the GLP-1 hormone to curb appetite and promote fullness, usually alongside diet and exercise, as part of a phased dosage increase.
National Institutes of Health (.gov)
National Institutes of Health (.gov)
+4
Key Details for Semaglutide 2.4 mg

Semaglutide injection is a weekly, subcutaneous GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management in adults. It functions by reducing appetite and aiding in weight loss. Common side effects include nausea, vomiting, and diarrhea.
1mg
1mg
+4
Key Information for Semaglutide Injection
Administration: It is injected under the skin (subcutaneous) in the abdomen, thigh, or upper arm once weekly.
Mechanism: It mimics GLP-1 to enhance insulin secretion and increase feelings of fullness.
Side Effects: Nausea, vomiting, diarrhea, constipation, and headache are common.
Serious Risks: Warnings include potential